Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 1:21 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: placebo Clear all

Conditions: Bipolar I Disorder
Interventions: Inhaled Placebo, Inhaled loxapine 5 mg, Inhaled loxapine 10 mg; Drug
Lead sponsor: Alexza Pharmaceuticals, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 6
States / cities: Escondido, California • Garden Grove, California • Atlanta, Georgia + 3 more

Conditions: Allergic Rhinitis
Interventions: Ibuprofen, Fluticasone propionate, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Tranexamic Acid, Cancer, Major Surgery
Interventions: Tranexamic Acid, Placebo; Drug · Other
Lead sponsor: Corewell Health West; Other
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Grand Rapids, Michigan

Conditions: Cerebral Palsy, GERD
Interventions: Baclofen, placebo; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 3 Years to 18 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Healthy
Interventions: HNC042 single dose, Placebo single dose, HNC042 multiple ascending doses, Placebo multiple ascending doses; Drug
Lead sponsor: Guangzhou Henovcom Bioscience Co. Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Resistance Training, Caffeine, Dietary Supplements
Interventions: Caffeinated pre-workout supplement, Non-caffeinated pre-workout supplement, Placebo; Dietary Supplement
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Infection, Pregnancy
Interventions: Placebo, Probiotic dietary supplement; Drug · Dietary Supplement
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 251 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2017
U.S. locations: 3
States / cities: Aptos, California • Santa Cruz, California • Stanford, California

Conditions: Colchicine Mechanism of Action
Interventions: Colchicine Tablets, Placebo oral tablet; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 50 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Arterial Hypertension
Interventions: Sotatercept, Placebo; Drug · Other
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 173 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 26
States / cities: Phoenix, Arizona • Los Angeles, California • Orange, California + 22 more

Conditions: Crohn's Disease
Interventions: Rifaximin EIR, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 78
States / cities: Huntsville, Alabama • Tucson, Arizona • Sherwood, Arkansas + 68 more

Conditions: Type 2 Diabetes Mellitus
Interventions: Ursodiol; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Deep Venous Thrombosis
Interventions: Idrabiotaparinux sodium, Idraparinux sodium, Avidin, Placebo (for Avidin); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 757 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Knee Osteoarthritis
Interventions: celecoxib; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 45 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Peripheral Neuropathy
Interventions: Diode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System; Procedure · Drug · Diagnostic Test + 1 more
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Palo Alto, California • Salt Lake City, Utah

Conditions: Chronic Kidney Disease
Interventions: BAY3283142, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 24
States / cities: Huntsville, Alabama • Chula Vista, California • San Dimas, California + 20 more

Conditions: Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: metformin hydrochloride, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 3
States / cities: Tucson, Arizona • Los Angeles, California

Conditions: Autism Spectrum Disorder
Interventions: Folinic Acid, Placebo; Drug · Other
Lead sponsor: Southwest Autism Research & Resource Center; Other
Eligibility: 5 Years to 17 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Phoenix, Arizona • Atlanta, Georgia • Lexington, Massachusetts + 1 more

Conditions: Bipolar Disorder
Interventions: JNJ-18038683, Placebo; Drug
Lead sponsor: Herbert Meltzer; Other
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rhinitis, Allergic, Perennial
Interventions: Placebo, Montelukast, Fluticasone propionate; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 55 Years
Enrollment: 102 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Alzheimer's Disease, Mild Cognitive Impairment
Interventions: Donepezil, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Long Beach, California • Hallandale, Florida • Lady Lake, Florida + 5 more

Conditions: Metabolism and Nutrition Disorder, Obesity
Interventions: NNC 0070-0002-0453, '2-0453, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Atherosclerosis
Interventions: SB 480848, tablets; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more

Conditions: Healthy
Interventions: MK-1167, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Atherosclerosis
Interventions: Spironolactone, Placebo; Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 41 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

Staccato Loxapine in Agitated Patients With Bipolar Disorder

A Study To Explore The Effect On Inflammatory Markers After Nasal Allergen Challenge In Subjects With Seasonal Allergic Rhinitis And The Effect Of A Single Dose Of Ibuprofen Or Fluticasone Propionate On The Allergen Response.

TXA Study in Major Oncologic Surgery

Placebo Controlled Study of Baclofen for GERD in Children With Cerebral Palsy

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Influence of Caffeinated and Non-caffeinated Pre-workout Supplements on Resistance Exercise Performance

Effects of Oral Probiotic Supplementation on Group B Strep (GBS) Rectovaginal Colonization in Pregnancy

Revisiting the Mechanism of the Anti-inflammatory Effect of Colchicine

A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/ZENITH)

One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease

Ursodiol on Insulin Sensitivity, Gastric Emptying and Body Weight With Type 2 Diabetes on Metformin

Bioequipotency Study of Idrabiotaparinux and Idraparinux in Patients With Deep Venous Thrombosis of the Lower Limbs

Efficacy of Celecoxib vs Placebo to Prevent Pain in a Paced Walk

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease

Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery

Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder

Testing the Ability of JNJ-18038683 to Improve Cognition and Reduce Depressive Symptoms in Stable Bipolar Patients

The Addition of Montelukast to Fluticasone in the Treatment of Perennial Allergic Rhinitis

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

A Two Part Trial Investigating an Anti-obesity Drug in Overweight/Obese Male and Female Healthy Volunteers

A Study To Determine The Effect Of SB-480848 On Asthma

A Study of MK-1167 in Healthy Elderly Participants (MK-1167-004)

Mineralocorticoid Receptor Antagonism Clinical Evaluation in Atherosclerosis Trial